The purpose of this study was to evaluate progression-free survival (PFS) and objective response rate (ORR) as surrogate endpoints of overall survival (OS) in modern clinical trials investigating the efficacy of targeted agents in the second-line treatment of metastatic colorectal cancer (mCRC). Materials and Methods A systematic search of literature pertaining to randomized phase II and III trials evaluating targeted agents as second-line treatments for mCRC was performed. The strength of the correlation between both PFS and ORR and OS was assessed based on the Pearson's correlation coefficient (R) and the coefficient of determination (R2). Results Twenty trials, including a total of 7,571 patients, met the search criteria. The median duration of post-progression survival (PPS) was 7.6 months. The median differences between experimental and control arms were 0.65 months (range, -2.4 to 3.4) for the median PFS and 0.7 months (range, -5.8 to 3.9) for the median OS. PFS and ORR showed moderate (R=0.734, R2=0.539, p < 0.001) and poor correlation (R=0.169, R2=0.029, p=0.476) with OS, respectively. No differences between anti-angiogenic agents and other drugs were evident. Conclusion Targeted agents investigated in the second-line treatment of mCRC provided minimal PFS gains translating into modest OS improvements. Considering both the moderate correlation between PFS and OS and the short duration of PPS, the OS should remain the preferred primary endpoint for randomized clinical trials in the second-line treatment of mCRC.

Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer : A Literature-Based Systematic Review and Meta-Analysis / C. Cremolini, C. Antoniotti, F. Pietrantonio, R. Berenato, M. Tampellini, C. Baratelli, L. Salvatore, F. Marmorino, B. Borelli, F. Nichetti, P. Bironzo, C. Sonetto, M.D. Bartolomeo, F. de Braud, F. Loupakis, A. Falcone, M.D. Maio. - In: CANCER RESEARCH AND TREATMENT. - ISSN 1598-2998. - 49:3(2017 Jul), pp. 834-845. [10.4143/crt.2016.249]

Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer : A Literature-Based Systematic Review and Meta-Analysis

F. Pietrantonio;F. Nichetti;F. de Braud;
2017-07

Abstract

The purpose of this study was to evaluate progression-free survival (PFS) and objective response rate (ORR) as surrogate endpoints of overall survival (OS) in modern clinical trials investigating the efficacy of targeted agents in the second-line treatment of metastatic colorectal cancer (mCRC). Materials and Methods A systematic search of literature pertaining to randomized phase II and III trials evaluating targeted agents as second-line treatments for mCRC was performed. The strength of the correlation between both PFS and ORR and OS was assessed based on the Pearson's correlation coefficient (R) and the coefficient of determination (R2). Results Twenty trials, including a total of 7,571 patients, met the search criteria. The median duration of post-progression survival (PPS) was 7.6 months. The median differences between experimental and control arms were 0.65 months (range, -2.4 to 3.4) for the median PFS and 0.7 months (range, -5.8 to 3.9) for the median OS. PFS and ORR showed moderate (R=0.734, R2=0.539, p < 0.001) and poor correlation (R=0.169, R2=0.029, p=0.476) with OS, respectively. No differences between anti-angiogenic agents and other drugs were evident. Conclusion Targeted agents investigated in the second-line treatment of mCRC provided minimal PFS gains translating into modest OS improvements. Considering both the moderate correlation between PFS and OS and the short duration of PPS, the OS should remain the preferred primary endpoint for randomized clinical trials in the second-line treatment of mCRC.
Biomarkers; Colorectal neoplasms; Molecular targeted therapy
Settore MED/06 - Oncologia Medica
15-nov-2016
CANCER RESEARCH AND TREATMENT
Article (author)
File in questo prodotto:
File Dimensione Formato  
crt-2016-249.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 408.59 kB
Formato Adobe PDF
408.59 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/514496
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact